20(S)-Ginsenoside-Rg3

20(S)-人参皂苷Rg3

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug Name20(S)-Ginsenoside-Rg3
Drug Alias NameGinsenoside Rg320(S)人参皂苷Rg320(S)-Propanaxidiol20（S）人参皂苷Rg3
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel subunit Kv11.1 agonistsPhosphatidylinositol 4-kinase activatorsSodium channel protein type II alpha subunit blockers +[5] 
TargetsSodium channel protein type II alpha subunitNeuronal acetylcholine receptor; alpha9/alpha10Phosphatidylinositol 4-kinase +[5] 
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesBeijing Xinliheng Medical Technology Development Co LtdUnigene Laboratories IncJilin University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Oriental Hepatobiliary Surgery Hospital
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A